A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined With Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer
Latest Information Update: 12 Jun 2025
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Iadademstat (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms CRADA-MSKCC; CTEP-CRADA
Most Recent Events
- 15 Apr 2025 According to an ORYZON media release, the first patient has been dosed in this trial.
- 03 Dec 2024 Planned End Date changed from 31 Jan 2026 to 25 Jul 2029.
- 03 Dec 2024 Planned primary completion date changed from 31 Jan 2026 to 25 Jul 2029.